Agenus shared on LinkedIn:
“We’re pleased to welcome Tim Hanke to Agenus as Head of Global Scientific Affairs, effective August 17.
Tim brings nearly four decades of global biotechnology and pharmaceutical leadership across oncology, with extensive experience building medical and scientific organizations, developing trusted relationships with leading investigators and scientific experts, and advancing clinical programs from development through commercialization.
At Agenus, Tim will lead our global scientific affairs and engagement strategy, working closely with investigators, academic institutions, and cross-functional teams to support our priority clinical programs, including the ROBBIN Phase 3 study.
His experience across immuno-oncology, colorectal cancer, global clinical development, and scientific engagement will be an important addition as we continue advancing BOT+BAL, accelerating ROBBIN, and expanding our engagement with the oncology community worldwide.
Learn more about Tim and his experience.”
